Economic Evaluation of Heart Failure Management in Colombian Clinics (EconoHeart)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: March 9, 2010
Last updated: NA
Last verified: March 2010
History: No changes posted
Cost effectiveness analysis of local management of patients diagnosed with heart failure disease compared with an ideal guideline-based management.

Heart Failure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Economic Evaluation of Heart Failure Management in Colombian Clinics

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To determine cost-effectiveness of Heart Failure management in 3 Heart-specialized clinics in Bogotá Colombia [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Incremental cost-effectiveness ratio from using Symbicort as symbicort as Maintenance and Reliever Therapy (SMART) when compared with its competitive alternatives [ Designated as safety issue: No ]

Enrollment: 300
Study Start Date: January 2008
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
moderate to severe uncontrolled asthma


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Moderate to severe uncontrolled asthma.

Inclusion Criteria:

  • Asthma moderate to severe.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01084564

Sponsors and Collaborators
Study Director: Rodolfo Dennis, M.D. Pontificia Universidad Javeriana
Principal Investigator: MARÍA XIMENA ROJAS, M.D. Pontificia Universidad Javeriana
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca Identifier: NCT01084564     History of Changes
Other Study ID Numbers: NIS-CCO-ATA-2007/1
Study First Received: March 9, 2010
Last Updated: March 9, 2010
Health Authority: Colombia: Institutional Review Board

Keywords provided by AstraZeneca:
Cost-effectiveness analysis

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases processed this record on December 01, 2015